HIGHLIGHTS
- who: Yoshiko Kitazume from the DepartmentKeio University have published the research: Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study, in the Journal: Scientific Reports Scientific Reports of December/31,/2019
SUMMARY
The median age of the patients was 63 years, 328 (54.1%) were males, 171 (28.2%) had right-sided colon cancer, and 533 (88.0%) had stage III CRC. Among patients who received capecitabine monotherapy, the median relative dose intensity (RDI) of capecitabine was 66.1% (IQR: 50.9-74.1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.